Denosumab: Benefits of RANK ligand inhibition in cancer patients

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 3, 2011, Pages 258-264

  Lipton, Allan ^a,b   Jacobs, Ira ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

Denosumab; Giant cell tumor of bone; Metastases; RANK ligand

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

BONE; BONE TUMOR; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; METASTASIS; MULTIPLE MYELOMA; REVIEW;

ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; RANK LIGAND;

EID: 80052753612     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328349731c     Document Type: Review

References (45)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s-6249s. (Pubitemid 44703797)
2. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2:205-213; discussion 213-204, 216-207, 219-220. (Pubitemid 39409755)
3. Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009; 273:177-193.
4. Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw 2009; 7:S1-29.
5. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 2005; 56:365-378. (Pubitemid 41677618)
6. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008; 34:92-101. (Pubitemid 351181016)
7. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145:527-538. (Pubitemid 29215717)
8. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157:435-448. (Pubitemid 30626907)
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176. (Pubitemid 28180851)
10. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329-1337. (Pubitemid 28510154)
11. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97:1566-1571. (Pubitemid 30118482)
12. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 350:1655- 1664.
13. Yonou H, Ochiai A, Goya M, et al. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004; 58:406-413. (Pubitemid 38295034)
14. Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A 1987; 84:2024-2028. (Pubitemid 17054142)
15. Mundy GR, Chen D, Zhao M, et al. Growth regulatory factors and bone. Rev Endocr Metab Disord 2001; 2:105-115. (Pubitemid 33643897)
16. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANKexpressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008; 68:92-104.
17. Buijs JT, Que I, Lowik CW, et al. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009; 44:380-386.
18. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25:119-129.
19. Feeley BT, Liu NQ, Conduah AH, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006; 21:1571-1580. (Pubitemid 44484602)
20. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581- 11586. (Pubitemid 32928771)
21. Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40:471-478. (Pubitemid 46070226)
22. Canon J, Bryant R, Roudier M, et al. Inhibition of RANKL increases the antitumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010; 46:1613-1619. This preclinical study using a mouse model of bone metastasis found that reduction of tumor-induced osteolysis by RANKL inhibition occurred through the indirect mechanism of reducing osteoclast-mediated bone resorption and increased the antitumor effect of panitumumab, and epidermal growth factor receptor inhibitor.
23. Holland PM, Miller R, Jones J, et al. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 2010; 9:539-550. This preclinical study showed that the combination of a RANKL inhibitor and a proapoptotic receptor agonist produced greater effects on reducing skeletal tumor burden than either agent alone in a bone metastasis model. These findings suggest that combination therapy with agents that inhibit bone resorption and agents that directly target tumors may be beneficial in the treatment of metastatic bone disease.
24. Miller RE, Roudier M, Jones J, et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008; 7:2160-2169.
25. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestininduced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103-107. This preclinical study provides evidence that RANKL acts directly on hormoneinduced mammary epithelium at the early stages of mammary tumorigenesis and suggests a potential role for RANKL inhibition in the treatment of proliferative breast disease.
26. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468:98-102. Findings from this preclinical study suggest that RANK/RANKL signaling is involved in progestin-induced breast cancer. Mammary-specific inhibition of RANKL signaling reduced the incidence of invasive carcinomas.
27. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-553. This preclinical study examined the role of RANKL signaling in mammary cancer metastasis and found that RANKL produced by tumor-infiltrating T cells promoted pulmonary metastasis of mammary tumors in mice.
28. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564- 1571.
29. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-4437. (Pubitemid 350013849)
30. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822. This phase 3, multicenter, double-blinded randomized clinical trial compares the safety and efficacy of denosumab and zoledronic acid in men with bone metastasis secondary to castration-resistant prostate cancer. Results from this study showed that denosumab was superior to zoledronic acid in delaying or preventing first onstudy SRE.
31. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132. This phase 3, multicenter, double-blinded, randomized clinical trial compares the safety and efficacy of denosumab with zoledronic acid in patients with advanced cancer and bone metastasis or with osteolytic lesions from myeloma. Results from this study show that denosumab was noninferior to zoledronic acid in preventing or delaying a first on-study SRE.
32. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132- 5139. This phase 3, multicenter, double-blinded randomized clinical trial compares the safety and efficacy of denosumab and zoledronic acid in patients with bone metastasis and advanced breast cancer. Results from this study showed that denosumab was superior to zoledronic acid in preventing a first on-study SRE.
33. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67:2-12.
34. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-102.
35. Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumor of bone. Lancet Oncol 2010; 11:815.
36. XGEVA US Prescribing Information. Amgen Inc., Thousand Oaks, CA.
37. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents. Cancer Invest 2009; 27:221-226.
38. Launay-Vacher V, Gligorov J, Le Tourneau C, et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010; 124:745-753.
39. Oh WK, Proctor K, Nakabayashi M, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007; 109:1090-1096. (Pubitemid 46435387)
40. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368- 379. (Pubitemid 17235084)
41. Zometa US Prescribing Information. Novartis, East Hanover, NJ.
42. Stopeck AT, Lipton A, Body JJ, et al. Denosumab for bone metastases from breast cancer: a new therapy option? Reply toM.S. Aapro. J Clin Oncol 2011; 29:e421-e423.
43. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol 2009; 21:338-344.
44. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11:275- 280. This open-label phase 2 study examines the therapeutic potential of denosumab in patients with recurrent or unresectable giant-cell tumor of bone. Denosumab treatment was associated with a complete or near complete reduction in giant cells and suppression of bone turnover.
45. Smith M, Saad F, Coleman R, et al. Denosumab to prolong bone metastasisfree survival in men with castrate-resistant prostate cancer: results of a global, phase 3 randomized, double-blind trial. American Urological Association May 14-19, 2011, Washington, DC.